Advanced in Ewing Sarcoma

Dr. Kenneth J. Cohen

Pediatric Hematology Oncology

Johns Hopkins Health System

Johns Hopkins University

5759 Cedar Ln,

Columbia, MD

Clinical Trials:Currently Recruiting for 2 Trials

Advanced in Ewing Sarcoma

Johns Hopkins Health System

Johns Hopkins University

5759 Cedar Ln,

Columbia, MD

OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Kenneth Cohen is a Pediatric Hematologist Oncology provider in Columbia, Maryland. Dr. Cohen is rated as an Advanced provider by MediFind in the treatment of Ewing Sarcoma. His top areas of expertise are Glioma, Medulloblastoma, Brain Stem Cancer, Embryonal Tumor with Multilayered Rosettes, and Bone Marrow Aspiration.

His clinical research consists of co-authoring 66 peer reviewed articles and participating in 41 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has participated in 9 clinical trials in the study of Ewing Sarcoma.

Specialties

Pediatric Hematology Oncology

Licenses

Internal Medicine in MD

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance

Find your insuranceClose

Accepted insurance plans:

Aetna

Blue Cross Blue Shield

Humana

HMO
INDEMNITY
POS
PPO

Johns Hopkins Healthcare

HMO
MANAGED MEDICAID PLAN
MEDICARE MAPD
MEDICARE-MEDICAID PLAN

Medicaid

OTHER MEDICAID
STATE MEDICAID

Wellcare

EPO
HMO
INSURANCE PLAN
MANAGED MEDICAID PLAN
MEDICARE MAPD
MEDICARE PDP
MEDICARE SNP
MEDICARE-MEDICAID PLAN
OTHER MEDICARE
OTHER MEDICARE PART D

View 1 Less Insurance Carrier -

Locations

JOHNS HOPKINS UNIVERSITY
5759 Cedar Ln, Columbia, MD 21044

Call: 443-718-3738

Other Locations

JOHNS HOPKINS UNIVERSITY
600 N Wolfe St, Blalock 266, Baltimore, MD 21287

Call: 410-502-4340

JOHNS HOPKINS UNIVERSITY
5755 Cedar Ln, Columbia, MD 21044

Call: 410-740-7544

Additional Areas of Focus

Dr. Cohen has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Immune Thrombocytopenic Purpura (ITP)

Neurofibromatosis Type 1 (NF1)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

40 Clinical Trials

A Phase 2 Study of Inotuzumab Ozogamicin (NSC# 772518) in Children and Young Adults With Relapsed or Refractory CD22+ B-Acute Lymphoblastic Leukemia (B-ALL)

Enrollment Status: Recruiting

Publish Date: September 18, 2025

Intervention Type: Drug, Procedure, Biological

Study Drugs: Cyclophosphamide, Cytarabine, Inotuzumab, Leucovorin, 6-Mercaptopurine, Pegaspargase, Vincristine

Study Phase: Phase 2

A Target Validation/Phase1 Study of BGB-290 in Combination With Temozolomide in Adolescent and Young Adult IDH1/2 Newly Diagnosed and Recurrent Mutant Gliomas

Enrollment Status: Recruiting

Publish Date: August 01, 2025

Intervention Type: Drug

Study Drugs: BGB-290, Temozolomide

Study Phase: Phase 1

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 Subprotocol of Ensartinib in Patients With Tumors Harboring ALK or ROS1 Genomic Alterations

Enrollment Status: Active_not_recruiting

Publish Date: October 07, 2025

Intervention Type: Procedure, Other, Drug

Study Drug: Ensartinib

Study Phase: Phase 2

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of BVD-523FB (Ulixertinib) in Patients With Tumors Harboring Activating MAPK Pathway Mutations

Enrollment Status: Active_not_recruiting

Publish Date: September 24, 2025

Intervention Type: Other, Drug

Study Drug: Ulixertinib

Study Phase: Phase 2

An Open Label, Multi-center Roll-over Study to Assess Long-term Effect in Pediatric Patients Treated With Tafinlar (Dabrafenib) and/or Mekinist (Trametinib)

Enrollment Status: Active_not_recruiting

Publish Date: September 24, 2025

Intervention Type: Drug

Study Drugs: Dabrafenib, Trametinib

Study Phase: Phase 4

A Phase 2 Study of Veliparib (ABT-888) and Local Irradiation, Followed by Maintenance Veliparib and Temozolomide, in Patients With Newly Diagnosed High-Grade Glioma (HGG) Without H3 K27M or BRAFV600 Mutations

Enrollment Status: Active_not_recruiting

Publish Date: September 19, 2025

Intervention Type: Drug, Radiation

Study Drugs: Temozolomide, Veliparib

Study Phase: Phase 2

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Erdafitinib in Patients With Tumors Harboring FGFR1/2/3/4 Alterations

Enrollment Status: Active_not_recruiting

Publish Date: September 19, 2025

Intervention Type: Procedure, Other, Drug

Study Drug: Erdafitinib

Study Phase: Phase 2

International Phase 3 Trial in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Testing Imatinib in Combination With Two Different Cytotoxic Chemotherapy Backbones

Enrollment Status: Active_not_recruiting

Publish Date: September 19, 2025

Intervention Type: Drug, Procedure, Other, Biological

Study Drugs: Cyclophosphamide, Cytarabine, Daunorubicin Hydrochloride, Dexamethasone, Dexrazoxane Hydrochloride, Doxorubicin, Etoposide, Filgrastim, Ifosfamide, Imatinib Mesylate, Leucovorin Calcium, Mercaptopurine, Methotrexate, Methylprednisolone, Pegaspargase, Prednisolone, Hydrocortisone, Thioguanine, Vincristine Sulfate

Study Phase: Phase 3

A Phase 2 Study of Dabrafenib (NSC# 763760) With Trametinib (NSC# 763093) After Local Irradiation in Newly-Diagnosed BRAF V600-Mutant High-Grade Glioma (HGG)

Enrollment Status: Active_not_recruiting

Publish Date: September 18, 2025

Intervention Type: Procedure, Radiation, Drug

Study Drugs: Dabrafenib Mesylate, Trametinib Dimethyl Sulfoxide

Study Phase: Phase 2

Neuropsychological, Social, Emotional, and Behavioral Outcomes in Children With Cancer

Enrollment Status: Active_not_recruiting

Publish Date: September 18, 2025

Intervention Type: Other, Procedure

PNOC 001: Phase II Study of Everolimus for Recurrent or Progressive Low-grade Gliomas in Children

Enrollment Status: Completed

Publish Date: September 09, 2025

Intervention Type: Drug

Study Drug: Everolimus

Study Phase: Phase 2

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol

Enrollment Status: Active_not_recruiting

Publish Date: September 03, 2025

Intervention Type: Procedure, Drug, Other

Study Drugs: Ensartinib, Erdafitinib, Larotrectinib, Olaparib, Palbociclib, Samotolisib, Selpercatinib, Selumetinib Sulfate, Tazemetostat, Tipifarnib, Ulixertinib, Vemurafenib

Study Phase: Phase 2

A Phase 3 Trial Investigating Blinatumomab (NSC# 765986) in Combination With Chemotherapy in Patients With Newly Diagnosed Standard Risk or Down Syndrome B-Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients With Localized B-Lymphoblastic Lymphoma (B-LLy)

Enrollment Status: Active_not_recruiting

Publish Date: August 21, 2025

Intervention Type: Drug, Biological, Radiation

Study Drugs: Erwinia Asparaginase, Blinatumomab, Cyclophosphamide, Cytarabine, Dexamethasone, Doxorubicin Hydrochloride, Leucovorin Calcium, Mercaptopurine, Methotrexate, Pegaspargase, Prednisolone, Prednisone, Thioguanine, Vincristine Sulfate

Study Phase: Phase 3

A Phase 2 Study of Reduced Therapy for Newly Diagnosed Average-Risk WNT-Driven Medulloblastoma Patients

Enrollment Status: Active_not_recruiting

Publish Date: August 12, 2025

Intervention Type: Drug, Procedure, Radiation, Other

Study Drugs: Cisplatin, Cyclophosphamide, Lomustine, Vincristine, Vincristine Sulfate

Study Phase: Phase 2

A Phase 3 Study of Selumetinib (NSC# 748727) or Selumetinib in Combination With Vinblastine for Non-NF1, Non-TSC Patients With Recurrent or Progressive Low-Grade Gliomas (LGGs) Lacking BRAFV600E or IDH1 Mutations

Enrollment Status: Active_not_recruiting

Publish Date: August 07, 2025

Intervention Type: Other, Procedure, Drug

Study Drugs: Selumetinib, Vinblastine

Study Phase: Phase 3

Pediatric Neuro-Oncology Consortium (PNOC)-002: Safety, Phase 0, and Pilot Efficacy Study of Vemurafenib, an Oral Inhibitor of BRAFV600E, in Children and Young Adults With Recurrent/Refractory BRAFV600E- or BRAF Ins T Mutant Brain Tumors

Enrollment Status: Completed

Publish Date: August 03, 2025

Intervention Type: Drug

Study Drug: Vemurafenib

Study Phase: Early Phase 1

Risk-Stratified Therapy for Acute Myeloid Leukemia in Down Syndrome

Enrollment Status: Active_not_recruiting

Publish Date: August 01, 2025

Intervention Type: Drug, Other

Study Drugs: Asparaginase, Erwinia Asparaginase, Cytarabine, Daunorubicin, Etoposide, Mitoxantrone, Thioguanine

Study Phase: Phase 3

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 Subprotocol of Tipifarnib in Patients With Tumors Harboring HRAS Genomic Alterations

Enrollment Status: Active_not_recruiting

Publish Date: July 28, 2025

Intervention Type: Drug

Study Drug: Tipifarnib

Study Phase: Phase 2

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of AG-120 (Ivosidenib) in Patients With Tumors Harboring IDH1 Mutations

Enrollment Status: Active_not_recruiting

Publish Date: July 28, 2025

Intervention Type: Drug

Study Drug: Ivosidenib

Study Phase: Phase 2

A Phase 3 Randomized Study of Selumetinib Versus Carboplatin/Vincristine in Newly Diagnosed or Previously Untreated Neurofibromatosis Type 1 (NF1) Associated Low-Grade Glioma (LGG)

Enrollment Status: Active_not_recruiting

Publish Date: July 28, 2025

Intervention Type: Other, Procedure, Drug

Study Drugs: Carboplatin, Selumetinib Sulfate, Vincristine Sulfate

Study Phase: Phase 3

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of LOXO-292 in Patients With Tumors Harboring RET Gene Alterations

Enrollment Status: Active_not_recruiting

Publish Date: July 28, 2025

Intervention Type: Procedure, Drug

Study Drug: Selpercatinib

Study Phase: Phase 2

A Target Validation Study of Fimepinostat in Children and Young Adults With Newly Diagnosed Diffuse Intrinsic Pontine Glioma (DIPG), Recurrent Medulloblastoma, or Recurrent High-Grade Glioma (HGG)

Enrollment Status: Active_not_recruiting

Publish Date: July 11, 2025

Intervention Type: Drug, Procedure

Study Drug: Fimepinostat

Study Phase: Early Phase 1

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of LOXO-101 (Larotrectinib) in Patients With Tumors Harboring Actionable NTRK Fusions

Enrollment Status: Active_not_recruiting

Publish Date: July 09, 2025

Intervention Type: Procedure, Drug

Study Drugs: Larotrectinib, Larotrectinib Sulfate

Study Phase: Phase 2

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Selumetinib (AZD6244 Hydrogen Sulfate) in Patients With Tumors Harboring Activating MAPK Pathway Mutations

Enrollment Status: Completed

Publish Date: February 05, 2025

Intervention Type: Drug, Other

Study Drugs: Selumetinib, Selumetinib Sulfate

Study Phase: Phase 2

A Phase I Study of Tovorafenib/DAY101 (Formerly TAK-580, MLN2480) for Children With Low-Grade Gliomas and Other RAS/RAF/MEK/ERK Pathway Activated Tumors

Enrollment Status: Active_not_recruiting

Publish Date: February 03, 2025

Intervention Type: Drug

Study Drug: DAY101

Study Phase: Phase 1

NCI-COG Pediatric MATCH (Molecular Analysis For Therapy Choice)- Phase 2 Subprotocol of LY3023414 in Patients With Solid Tumors

Enrollment Status: Completed

Publish Date: January 27, 2025

Intervention Type: Procedure, Drug

Study Drug: Samotolisib

Study Phase: Phase 2

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 Subprotocol of Vemurafenib in Patients With Tumors Harboring BRAF V600 Mutations

Enrollment Status: Completed

Publish Date: January 27, 2025

Intervention Type: Other, Drug

Study Drug: Vemurafenib

Study Phase: Phase 2

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Tazemetostat in Patients With Tumors Harboring Alterations in EZH2 or Members of the SWI/SNF Complex

Enrollment Status: Completed

Publish Date: January 27, 2025

Intervention Type: Drug

Study Drug: Tazemetostat

Study Phase: Phase 2

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- A Phase 2 Subprotocol of Olaparib in Patients With Tumors Harboring Defects in DNA Damage Repair Genes

Enrollment Status: Completed

Publish Date: December 11, 2024

Intervention Type: Drug

Study Drug: Olaparib

Study Phase: Phase 2

COOrdinating CaRDIology CliNics RAndomized Trial of Interventions to Improve OutcomEs (COORDINATE) - Diabetes

Enrollment Status: Completed

Publish Date: November 21, 2024

Intervention Type: Other

Study Phase: Not Applicable

Phase 2 Trial of Response-Based Radiation Therapy for Patients With Localized Central Nervous System Germ Cell Tumors (CNS GCT)

Enrollment Status: Completed

Publish Date: November 19, 2024

Intervention Type: Drug, Radiation

Study Phase: Phase 2

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Palbociclib in Patients With Tumors Harboring Activating Alterations in Cell Cycle Genes

Enrollment Status: Completed

Publish Date: November 01, 2024

Intervention Type: Other, Drug

Study Drug: Palbociclib

Study Phase: Phase 2

Phase III Randomized Trial of Post-Radiation Chemotherapy in Patients With Newly Diagnosed Ependymoma Ages 1 to 21 Years

Enrollment Status: Active_not_recruiting

Publish Date: October 26, 2024

Intervention Type: Drug, Radiation, Biological, Other

Study Drugs: Carboplatin, Cisplatin, Cyclophosphamide, Etoposide, Vincristine

Study Phase: Phase 3

A Phase 1/2, Single-arm Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of Avapritinib in Pediatric Patients With Solid Tumors Dependent on KIT or PDGFRA Signaling

Enrollment Status: Active_not_recruiting

Publish Date: September 23, 2024

Intervention Type: Drug

Study Drug: Avapritinib

Study Phase: Phase 1/Phase 2

A Randomized, Blinded Study of Fluorescence Detection of Pediatric Primary Central Nervous System Tumors in Subjects Receiving Tozuleristide and Imaged With the Canvas System

Enrollment Status: Completed

Publish Date: June 27, 2024

Intervention Type: Device, Drug

Study Drug: Tozuleristide

Study Phase: Phase 2/Phase 3

A Randomized Phase 2 Trial of Brentuximab Vedotin (SGN35, NSC# 749710), or Crizotinib (NSC#749005, Commercially Labeled) in Combination With Chemotherapy for Newly Diagnosed Patients With Anaplastic Large Cell Lymphoma (ALCL)

Enrollment Status: Completed

Publish Date: April 30, 2024

Intervention Type: Drug

Study Drugs: Brentuximab Vedotin, Crizotinib, Cyclophosphamide, Cytarabine, Dexamethasone, Doxorubicin Hydrochloride, Etoposide, Ifosfamide, Methotrexate

Study Phase: Phase 2

Phase II Open-label Global Study to Evaluate the Effect of Dabrafenib in Combination With Trametinib in Children and Adolescent Patients With BRAF V600 Mutation Positive Low Grade Glioma (LGG) or Relapsed or Refractory High Grade Glioma (HGG)

Enrollment Status: Completed

Publish Date: December 13, 2023

Intervention Type: Drug

Study Drugs: Dabrafenib, Trametinib, Carboplatin with Vincristine

Study Phase: Phase 2

A Phase II Study for the Treatment of Non-metastatic Nodular Desmoplastic Medulloblastoma in Children Less Than 4 Years of Age

Enrollment Status: Completed

Publish Date: January 09, 2023

Intervention Type: Drug, Other

Study Drugs: Carboplatin, Cyclophosphamide, Etoposide, Methotrexate, Vincristine Sulfate

Study Phase: Phase 2

Phase I Study of Mebendazole Therapy for Recurrent/Progressive Pediatric Brain Tumors

Enrollment Status: Completed

Publish Date: June 23, 2022

Intervention Type: Drug

Study Drug: Mebendazole

Study Phase: Phase 1

A Children's Oncology Group Protocol for Collecting and Banking Pediatric Brain Tumor Research Specimens

Enrollment Status: Completed

Publish Date: July 16, 2018

Intervention Type: Other

View 38 Less Clinical Trials

64 Total Publications

Pediatric Central Nervous System Cancers, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: March 12, 2025

View All 64 Publications

Similar Doctors

Elite in Ewing Sarcoma

Dr. Jeffrey A. Toretsky

Pediatric Hematology Oncology

Elite in Ewing Sarcoma

Dr. Jeffrey A. Toretsky

Pediatric Hematology Oncology

3800 Reservoir Rd Nw,

Washington, DC

(23.3 miles away)

202-444-7599

Languages Spoken:

English

See accepted insurances

Jeffrey Toretsky is a Pediatric Hematologist Oncology provider in Washington, Washington, D.c.. Dr. Toretsky is rated as a Distinguished provider by MediFind in the treatment of Ewing Sarcoma. His top areas of expertise are Ewing Sarcoma, Osteosarcoma, Adult Soft Tissue Sarcoma, Rhabdomyosarcoma, and Bone Marrow Aspiration.

Distinguished in Ewing Sarcoma

Dr. Javed A. Khan

Pediatric Hematology Oncology

Distinguished in Ewing Sarcoma

Dr. Javed A. Khan

Pediatric Hematology Oncology

10 Center Drive,

Bethesda, MD

(18.7 miles away)

240-760-6135

Languages Spoken:

English

Javed Khan is a Pediatric Hematologist Oncology provider in Bethesda, Maryland. Dr. Khan is rated as an Elite provider by MediFind in the treatment of Ewing Sarcoma. His top areas of expertise are Rhabdomyosarcoma, Adult Soft Tissue Sarcoma, Neuroblastoma, Embryonal Tumor with Multilayered Rosettes, and Angioplasty.

Distinguished in Ewing Sarcoma

Dr. Christine M. Heske

Pediatric Hematology Oncology

Distinguished in Ewing Sarcoma

Dr. Christine M. Heske

Pediatric Hematology Oncology

10 Center Drive - Crc Building 10 - 1w-3816,

Bethesda, MD

(19.8 miles away)

301-451-7016

Languages Spoken:

English

Christine Heske is a Pediatric Hematologist Oncology provider in Bethesda, Maryland. Dr. Heske is rated as a Distinguished provider by MediFind in the treatment of Ewing Sarcoma. Her top areas of expertise are Rhabdomyosarcoma, Ewing Sarcoma, Adult Soft Tissue Sarcoma, Osteosarcoma, and Tissue Biopsy.

VIEW MORE EWING SARCOMA DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Cohen's expertise for a condition

ConditionClose